Pharmacokinetics of Treprostinil Sodium Administered by 28‐Day Chronic Continuous Subcutaneous Infusion
- 1 May 2004
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (5) , 503-509
- https://doi.org/10.1177/0091270004264638
Abstract
The objective of this study was to assess the pharmacokinetics and safety of treprostinil sodium administered as a 28-day continuous subcutaneous infusion at escalating infusion rates of 2.5 to 15 ng/kg/min in normal subjects. Fourteen healthy adult volunteers received a 28-day continuous sub-cutaneous infusion of treprostinil at escalating infusion rates of 2.5, 5, 10, and 15 ng/kg/min. Doses were escalated every 7 days with no washouts between escalations. Serial plasma samples were collected predosing, during dosing, and postdosing. Samples were also collected every 3 hours on Day 7 of each dosing period to evaluate diurnal variation over a 24-hour steady-state interval. Plasma treprostinil concentration was measured by a validated liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 25 pg/mL. Distinct steady states were achieved for each of the four treprostinil doses. Linear regression analysis of mean steady-state treprostinil concentration versus targeted dose yielded a fitted line with an r(2) of 0.92. Variation in apparent plasma clearance for the four doses was small (i.e., 9.77-10.4 mL/kg/min). Consistent diurnal cycles of two peak and two trough treprostinil concentrations were observed over a 24-hour steady-state interval for each dose with peak levels 20% to 30% higher than trough levels. The terminal half-life of treprostinil was 2.93 hours. Intersubject variability for mean pharmacokinetic parameters was small (coefficients of variation ranging from 13.6%-25.5%). At clinically relevant doses, the pharmacokinetics of treprostinil were linear and dose independent with modest, consistent diurnal cycles consisting of two daily peaks and two daily troughs observed for all four doses. In addition, the elimination half-life was about 3 hours.Keywords
This publication has 15 references indexed in Scilit:
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case SeriesAnnals of Internal Medicine, 1999
- Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart DefectsCirculation, 1999
- Treatment of pulmonary hypertension secondary to connective tissue diseasesThorax, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dogProstaglandins, Leukotrienes & Essential Fatty Acids, 1993
- Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous cathetersThe American Journal of Medicine, 1991
- The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogsProstaglandins, Leukotrienes & Essential Fatty Acids, 1991